Immunome Chief Business Officer Kinney Receives Stock Options and RSU Grant Worth Over $1.3 Million

Details of the Restricted Stock Unit Award for Immunome's Chief Business Officer

Horn Kinney, who serves as Chief Business Officer at Immunome Inc., received 31,250 restricted stock units on July 23, 2026, according to the company's beneficial ownership disclosure filed with the SEC. The filing indicates that each RSU represents a contingent right to receive one share of common stock upon settlement. The RSUs are scheduled to vest at 25% annually on each anniversary of the grant date, contingent upon Kinney's continuous service with the company through the respective vesting dates. This means that Kinney would receive approximately 7,812 shares per year for four years, assuming continuous employment.

The grant structure reflects a standard four-year vesting schedule commonly used by public companies to retain executive talent and encourage long-term commitment. No purchase price was required for the RSU grant, which is typical for equity compensation awards tied to continued employment. Following the transaction, Kinney holds 31,250 RSUs in direct beneficial ownership, representing the full amount granted on July 23, 2026. The vesting schedule ensures that executives maintain alignment with shareholder interests over an extended period.

Stock Options Grant with $22.01 Exercise Price Awarded to Kinney

In addition to the RSU award, Kinney received 62,500 employee stock options on the same date, July 23, 2026. The options carry an exercise price of $22.01 per share and have a ten-year term, expiring on July 22, 2036. The vesting structure differs slightly from the RSUs: 25% of the shares subject to the options will vest on July 23, 2027, which is approximately one year after the grant date. Following that initial vesting milestone, one-thirty-sixth of the remaining shares will vest every month thereafter, subject to Kinney's continuous service. This structure means approximately 15,625 shares will vest on the first anniversary, with the remaining 46,875 shares vesting in monthly increments of approximately 1,302 shares per month over the subsequent 36 months.

The exercise price of $22.01 establishes the level at which Kinney can purchase shares of Immunome common stock during the option period. The combination of annual and monthly vesting schedules creates multiple incentive layers, encouraging executive retention across the vesting timeline. Following the grant, Kinney holds 62,500 options in direct beneficial ownership, all of which remain subject to the stated vesting conditions and service requirements.

Executive Compensation Strategy and Equity Alignment at Immunome

The equity grants awarded to Chief Business Officer Kinney demonstrate Immunome's approach to executive compensation through a mix of restricted stock units and stock options. This dual-grant structure is designed to balance immediate equity ownership incentives through RSUs with the growth potential offered by options. The company's use of both instruments suggests a compensation philosophy that addresses near-term retention through vesting RSUs while providing upside participation through options exercisable at a predetermined price. The $22.01 strike price for the options provides a baseline against which future share price appreciation can be measured.

The substantial size of both grants—31,250 RSUs and 62,500 options—indicates that Immunome has prioritized competitive equity compensation for senior management roles. The Chief Business Officer position typically carries broad responsibilities across corporate development, strategic partnerships, and business operations, justifying significant equity incentives. The four-year vesting schedule for RSUs and approximately four-year vest timeline for options (25% year one, then 36 monthly vests) align the executive's financial interests with shareholder returns over a multi-year horizon. This structure is consistent with governance practices at comparable biopharmaceutical companies.

Beneficial Ownership Changes Following the July 2026 Grant

Following the transaction dated July 23, 2026, Horn Kinney's beneficial ownership in Immunome Inc. increased by the full amount of both grants. The filing confirms that Kinney holds 31,250 RSUs and 62,500 options in direct beneficial ownership, with no indirect ownership arrangements noted. The disclosure provides a clear snapshot of Kinney's stake in the company as of the transaction date and establishes the baseline for future reporting of changes in beneficial ownership. All securities are held in direct form rather than through trusts, entities, or other indirect structures.

The timing of the grant on July 23, 2026, represents a discrete equity award event captured in the SEC's beneficial ownership tracking system. The filing was signed and submitted on July 27, 2026, four business days after the transaction, meeting regulatory reporting requirements. The document indicates that Sandra Stoneman, acting as Attorney-in-Fact, signed the Form 4 on Kinney's behalf, a common administrative practice for executive benefit filings. The submission of this disclosure ensures transparency regarding executive equity holdings and potential conflicts of interest among Immunome's senior management.

Vesting Conditions and Service Requirements for Kinney's Awards

Both the RSU grant and the stock option award to Kinney are contingent upon continuous service with Immunome Inc. through each respective vesting date. For the RSUs, vesting occurs on the anniversary of the grant date each year, provided Kinney remains employed by the company. The filing specifies that 25% of the RSUs will vest and settle into common stock annually, meaning the vesting dates would occur on July 23, 2027, July 23, 2028, July 23, 2029, and July 23, 2030, assuming no interruption in employment. This contingency structure is standard in equity compensation and aligns management retention with shareholder value creation.

The stock options follow a steeper initial vesting schedule but a longer overall vesting period. The first tranche of 25% vests on July 23, 2027, with the remaining 75% vesting in 36 equal monthly installments beginning in August 2027. This means Kinney would receive approximately 1,302 shares of option vesting per month from August 2027 through July 2030. If Kinney's employment terminates before a vesting date, any unvested options and RSUs would generally not vest unless the company's equity plan or an employment agreement provides for acceleration in specific circumstances such as a change of control or termination without cause. The filing does not indicate any accelerated vesting provisions or special circumstances applicable to these particular grants.

Timeline of Grant Execution and Regulatory Filing Submission

The equity award transaction occurred on July 23, 2026, when Immunome granted the RSUs and stock options to Chief Business Officer Kinney. This date marks the formal grant date for all compensation and vesting calculations. The regulatory filing was completed and submitted on July 27, 2026, providing public transparency regarding the equity grant within four business days of the transaction. The brief filing interval reflects the company's compliance with federal insider trading disclosure rules, which generally require Form 4 submissions within two business days of a transaction. The filing indicates that no deemed execution date applies to either transaction, meaning the July 23 date represents both the transaction date and the effective grant date.

The filing was signed by Sandra Stoneman as Attorney-in-Fact on July 27, 2026, authorizing submission on Kinney's behalf. The document carries standard SEC warnings regarding the criminal penalties for intentional misstatements or omissions of material facts, reinforcing the legal significance of the disclosure. The submission completed Immunome's public reporting obligations regarding this executive equity grant and added the transaction to the company's beneficial ownership record with the Securities and Exchange Commission.

Implications of the Grant for Immunome Shareholders and Governance

The award of significant equity to Chief Business Officer Kinney carries implications for Immunome shareholders regarding executive compensation levels and potential dilution of existing share ownership. The combined grant of approximately 93,750 securities (31,250 RSUs plus 62,500 options) represents a material incentive for a senior executive role. Shareholders may assess whether the grant size aligns with Immunome's financial performance, the executive's tenure and contributions, and comparable compensation practices in the biopharmaceutical industry. The $22.01 exercise price for the options establishes a reference point against which future performance can be evaluated, and shareholders may monitor whether this pricing reflects fair value relative to the company's stock performance following the grant date.

The equity grant structure also influences Kinney's interest alignment with shareholders. By tying substantial portions of compensation to share vesting and option exercise prices, Immunome creates incentives for the Chief Business Officer to pursue business strategies that increase shareholder value over the multi-year vesting period. However, the large absolute size of the grant, when combined with other potential equity awards and salary compensation, may represent a significant ongoing dilution consideration for the shareholder base. Shareholders evaluating governance practices and executive compensation may also note whether Kinney's compensation is disclosed through routine proxy disclosures or annual compensation reports that provide context regarding total compensation and peer comparisons.

Regulatory Compliance and Section 16 Reporting Requirements

The Form 4 filing demonstrates Immunome's compliance with Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and significant shareholders to report changes in beneficial ownership within specified timeframes. Horn Kinney's status as Chief Business Officer triggers Section 16 reporting requirements, making the disclosure of this equity grant mandatory. The filing clearly identifies Kinney as an officer rather than a director or 10% owner, establishing the basis for the reporting obligation. The company's address is listed as 18702 N. Creek Parkway, Suite 100, Bothell, Washington 98011, Immunome's principal office location.

The filing includes standard SEC certifications and warnings regarding the accuracy of reported information. The form indicates that it was filed by one reporting person (Kinney), not as a joint or group filing, and confirms that the transaction was not made pursuant to a Rule 10b5-1 trading plan. Rule 10b5-1 plans are designed to allow insiders to execute pre-arranged trading programs that satisfy affirmative defenses to insider trading liability; the absence of such a designation indicates that this equity grant was a standard compensation award rather than a discretionary open-market transaction. The filing requirement ensures transparency and allows investors to track insider equity positions and assess potential conflicts of interest in company decision-making.

Context of the Award Within Immunome's Corporate Structure

Immunome Inc. operates as a NASDAQ-listed company under the ticker symbol IMNM, positioning it within the biopharmaceutical and immunology sectors. As Chief Business Officer, Horn Kinney likely holds broad responsibilities encompassing corporate development, strategic partnerships, business operations, and potentially investor relations or financing initiatives. The substantial equity grant reflects the strategic importance of this role in a growth-focused biotech environment where strong business development capabilities can drive revenue growth, partnership success, and ultimately shareholder returns. The grant may also reflect competitive pressure to retain experienced executives in a talent market where biopharmaceutical companies actively compete for senior business operations talent.

The filing does not disclose Kinney's tenure with Immunome, prior compensation history, or comparative equity grants to other executives, limiting the ability to assess the grant's context within the company's broader compensation structure. Investors seeking additional compensation context would typically review Immunome's annual proxy statement (Schedule 14A), which discloses Named Executive Officer compensation in tabular format with peer comparisons and narrative explanation. The Form 4 filing provides the equity grant fact but not the broader compensation narrative necessary for comprehensive governance assessment. Public investors may monitor future proxy filings or quarterly reports for additional context regarding Kinney's role evolution and compensation philosophy at Immunome.